Carbazeran citrate
Modify Date: 2024-01-17 22:31:33
Carbazeran citrate structure
|
Common Name | Carbazeran citrate | ||
|---|---|---|---|---|
| CAS Number | 153473-94-0 | Molecular Weight | 552.531 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C24H32N4O11 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Carbazeran citrateCarbazeran (citrate), a potent phosphodiesterase inhibitor, is aldehyde oxidase substrate. Carbazeran (citrate) can be used for the research of metabolic disease[1]. |
| Name | 1-(6,7-Dimethoxy-1-phthalazinyl)-4-piperidinyl ethylcarbamate 2-hydroxy-1,2,3-propanetricarboxylate (1:1) |
|---|---|
| Synonym | More Synonyms |
| Description | Carbazeran (citrate), a potent phosphodiesterase inhibitor, is aldehyde oxidase substrate. Carbazeran (citrate) can be used for the research of metabolic disease[1]. |
|---|---|
| Related Catalog | |
| Target |
phosphodiesterase[1] |
| In Vivo | Carbazeran (10 mg/kg; p.o.) (citrate) of the unmetabolized in samples from humanized-liver mice, the mean plasma concentrations are lower than in those from control mice for 0.5~4 hours after oral administration[1]. Oral administration of carbazeran (citrate) to guinea pigs has reportedly resulted in large kinetic deuterium isotope effects on the AUC and Cmax, without a change of systemic half-life[1]. Animal Model: Mice[1] Dosage: 10 mg/kg Administration: P.o. Result: The mean plasma concentrations were lower than in those from control mice for 0.5~4 hours after oral administration. |
| References |
| Molecular Formula | C24H32N4O11 |
|---|---|
| Molecular Weight | 552.531 |
| Exact Mass | 552.206787 |
| 1-(6,7-Dimethoxy-1-phthalazinyl)-4-piperidinyl ethylcarbamate 2-hydroxy-1,2,3-propanetricarboxylate (1:1) |
| Carbamic acid, N-ethyl-, 1-(6,7-dimethoxy-1-phthalazinyl)-4-piperidinyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) |